"The TGA and its expert advisory committee, the Adverse Drug Reactions Advisory Committee (ADRAC), have urgently investigated these reports. ADRAC has today recommended the cancellation of the registration of Lumiracoxib due to the severity of the reported side effects associated with this drug," Dr Hammett said.

 
On January 17, 2008, the [[Philippines]] [[Department of Health]] ordered [[Novartis]] Healthcare Phils. Inc. (Novartis) to remove (recall) all lumiracoxib from local drug stores in 2 weeks due to the harmful effects of the drug (potential serious [[liver]]-related side effects, hepatotoxicity or malfunction of the [[lung]]s).<ref>[http://www.abs-cbnnews.com/storypage.aspx?StoryId=105842  Abs-Cbn Interactive, DOH recalls lumiracoxib, sets two-week deadline]</ref>
